The Motley Fool
27 Jun 2026, 19:15 UTC · 2h ago
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
27 Jun 2026, 19:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Pfizer's dividend payout ratio is currently 130% of earnings. — A payout ratio exceeding 100% suggests the dividend is unsustainable based on current earnings, raising the risk of a dividend cut.
-0.60Pfizer abandoned its internal GLP-1 weight-loss drug development in 2025, leaving it behind competitors Eli Lilly and Novo Nordisk. — Losing a foothold in the high-growth obesity market represents a significant loss of future revenue potential and competitive standing.
-0.50Pfizer is facing a 'patent cliff' with several blockbuster drugs set to lose patent protection in the next few years. — Patent expirations typically lead to immediate revenue drops as cheaper generics enter the market.
-0.40Continue reading
6 related stories
Search tags
Pfizer is offering a high dividend yield of approximately 6.9% to 7.27%. — While the yield is attractive for income investors, it is largely a result of the stock price collapsing.
+0.30Pfizer has acquired a company with an attractive GLP-1 candidate to recover its position in the weight-loss drug category. — This provides a potential strategic path back into the GLP-1 market, though it is a recovery effort rather than a lead.
+0.20Which stocks this story touches
Mentioned as an industry peer that is far ahead of Pfizer in the emerging weight-loss drug category.
Mentioned as an industry peer that is far ahead of Pfizer in the emerging weight-loss drug category.
While acknowledging significant struggles and a failed weight-loss drug, the author argues the stock is oversold and the company is taking the right steps for long-term recovery.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
